Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma

被引:2
|
作者
Bajestani, Nojan [1 ]
Wu, Gavin [1 ]
Hussein, Ahmed [1 ]
Makary, Mina S. [2 ]
机构
[1] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, Dept Radiol, Div Vasc & Intervent Radiol, 395 W 12th Ave, Columbus, OH 43210 USA
关键词
hepatocellular carcinoma; locoregional therapy; immunotherapy; combination therapy; progression-free survival; overall survival; PERCUTANEOUS RADIOFREQUENCY ABLATION; INTERNAL RADIATION-THERAPY; RANDOMIZED CONTROLLED-TRIAL; TRANSARTERIAL CHEMOEMBOLIZATION; OPEN-LABEL; PHASE-III; SURGICAL RESECTION; MICROWAVE ABLATION; Y-90; MICROSPHERES; SYSTEMIC THERAPY;
D O I
10.3390/biomedicines12071432
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
More than 800,000 people worldwide are diagnosed with HCC (hepatocellular carcinoma) each year, with approximately 700,000 deaths alone occurring in that same year. Treatment of HCC presents complex therapeutic challenges, particularly in intermediate and advanced stages. LRTs such as transarterial chemoembolization (TACE) and ablations have been the mainstay treatment for early to intermediate-stage HCC, and systemic therapies are used to treat intermediate-late-stage HCC. However, novel literature describing combining LRT with systemic therapies has shown promising results. This review explores recent advances in both liver-directed techniques for hepatocellular carcinoma, including bland transarterial embolization, chemoembolization, radioembolization, and ablative therapies in conjunction as well as with systemic therapies, with a focus on combination therapies, patient selection, procedural technique, periprocedural management, and outcomes. Our findings suggest that LRT combined with systemic therapies is a viable strategy for improving progression-free survival and time to progression for patients with intermediate-to-late-stage HCC. However, further investigation is required to refine treatment protocols and define patient cohorts that would benefit the most.
引用
收藏
页数:30
相关论文
共 50 条
  • [31] Clinical Trials of Combined Molecular Targeted Therapy and Locoregional Therapy in Hepatocellular Carcinoma: Past, Present, and Future
    Kim, Hwi Young
    Park, Joong-Won
    LIVER CANCER, 2014, 3 (01) : 9 - 17
  • [32] Single-cell sequencing reveals differential efficacy of targeted therapy combined with immunotherapy in patients with hepatocellular carcinoma
    Zhang, Boxiang
    Song, Xin
    Chen, Xiyao
    Zheng, Xingrong
    Pan, Tao
    Xie, Chan
    Peng, Liang
    JOURNAL OF HEPATOLOGY, 2024, 80 : S430 - S430
  • [33] The efficacy and safety of avatrombopag in the treatment of thrombocytopenia secondary to targeted and immunotherapy in hepatocellular carcinoma
    Peng, X.
    Wu, K.
    Wang, L.
    Wang, Z.
    You, N.
    Zhang, H.
    Liu, Z.
    Zheng, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S1491 - S1491
  • [34] OUTCOMES OF POST-IMMUNOTHERAPY DURABLE RESPONDERS OF ADVANCED HEPATOCELLULAR CARCINOMA - WITH EMPHASIS ON LOCOREGIONAL THERAPY FOR OLIGOPROGRESSION
    Liu, Tsung-Hao
    Chen, San-Chi
    Rau, Kun-Ming
    Lu, Li-Chung
    Lin, Po-Ting
    Su, Yung-Yeh
    Teng, Wei
    Lai, Shiue-Wei
    Yehn, Ren-Hua
    Kao, Tsui-Mai
    Lee, Pei-Chang
    Wu, Chi-Jung
    Chen, Chien-Hung
    Hsu, Chih-Hung
    Lin, Shi-Ming
    Huang, Yi-Hsiang
    Chen, Li-Tzong
    Cheng, Ann-Lii
    Shen, Ying-Chun
    HEPATOLOGY, 2022, 76 : S1411 - S1412
  • [35] Nonrigid Registration for Evaluating Locoregional Therapy of Hepatocellular Carcinoma
    Dong, Chunhua
    Seki, Toshihito
    Inoguchi, Ryosuke
    Lin, Chen-Lun
    Han, Xianhua
    Chen, Yen-Wei
    PROCEEDINGS OF THE 2013 6TH INTERNATIONAL CONFERENCE ON BIOMEDICAL ENGINEERING AND INFORMATICS (BMEI 2013), VOLS 1 AND 2, 2013, : 811 - 816
  • [36] Pretransplant locoregional therapy for hepatocellular carcinoma: encouraging but insufficient
    Kim, Seong Hoon
    Lee, Eung Chang
    Park, Sang Jae
    HEPATOBILIARY SURGERY AND NUTRITION, 2018, 7 (02) : 136 - 137
  • [37] Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread
    Leal, Julie N.
    Gonen, Mithat
    Covey, Anne M.
    Erinjeri, Joseph P.
    Getrajdman, George
    Sofocleous, Constantinos T.
    D'Angelica, Michael
    DeMatteo, Ronald P.
    Abou-Alfa, Ghassan K.
    Jarnagin, William R.
    Fong, Yuman
    Brown, Karen T.
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2015, 26 (08) : 1112 - 1121
  • [38] MRI assessment of hepatocellular carcinoma after locoregional therapy
    Rasha S. Hussein
    Wahid Tantawy
    Yasser A. Abbas
    Insights into Imaging, 10
  • [39] The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma
    Brandi, Nicolo
    Renzulli, Matteo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (10)
  • [40] MRI assessment of hepatocellular carcinoma after locoregional therapy
    Hussein, Rasha S.
    Tantawy, Wahid
    Abbas, Yasser A.
    INSIGHTS INTO IMAGING, 2019, 10 (01)